Evidence map›Paper›PMID 36945827›Full record

ArticleBMB reports2023

Recombinant human KAI1/CD82 attenuates M1 macrophage polarization on LPS-stimulated RAW264.7 cells via blocking TLR4/JNK/NF-κB signal pathway.

Hyesook Lee, Jung-Hwa Han, Kangbin An, Yun Jeong Kang, Hyun Hwangbo, Ji Hye Heo, Byung Hyun Choi, Jae-Joon Kim, Seo Rin Kim, Soo Yong Lee and 1 more

Open access · goldAbstract readNews
In one paragraph

Article in BMB reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. International journal of molecular sciences · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Hyesook LeeDepartment of Convergence Medicine, Pusan National University School of Medicine, Yangsan 50612, Korea.
Jung-Hwa HanDepartment of Convergence Medicine, Pusan National University School of Medicine, Yangsan 50612; PNU GRAND Convergence Medical Science Education Research Center, Pusan National University School of Medicine, Yangsan 50612, Korea.
Kangbin AnDepartment of Convergence Medicine, Pusan National University School of Medicine, Yangsan 50612; PNU GRAND Convergence Medical Science Education Research Center, Pusan National University School of Medicine, Yangsan 50612, Korea.
Yun Jeong KangDepartment of Convergence Medicine, Pusan National University School of Medicine, Yangsan 50612, Korea.
Hyun HwangboDepartment of Biochemistry, Dong-Eui University College of Korean Medicine, Busan 47227, Korea.
Ji Hye HeoDepartment of Biomedical Laboratory Science, Donggang University, Gwangju 61200, Korea.
Byung Hyun ChoiDivision of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan 50612, Korea.
Jae-Joon KimMedical Oncology and Hematology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan 50612, Korea.
Seo Rin KimDivision of Nephrology, Department of Internal Medicine, Pusan National University School of Medicine, Yangsan 50612, Korea.
Soo Yong LeeDivision of Cardiology, Department of Internal Medicine, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan 50612, Korea.
Jin HurDepartment of Convergence Medicine, Pusan National University School of Medicine, Yangsan 50612; PNU GRAND Convergence Medical Science Education Research Center, Pusan National University School of Medicine, Yangsan 50612; Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 50612, Korea.
Pusan National University · KRPusan National University Yangsan Hospital · KRDong-Eui University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

KAI1/CD82, a membrane tetraspanin protein, can prevent various cancers and retinal disorders through its anti-angiogenic and anti-metastatic capacity. However, little is known about its anti-inflammatory effect and molecular mechanism. Therefore, the present study aimed to inLPSvestigate effect of a recombinant protein of the large extracellular domain of human KAI1 (Gly 111-Leu 228, rhKAI1) on lipopolysaccharides (LPS)-stimulated RAW264.7 macrophage-like cells and mouse bone marrow-derived macrophages (BMDM) and to identify its underlying mechanism. Our data showed that rhKAI1 suppressed expression levels of classically macrophages (M1) phenotyperelated surface markers F4/80+CD86+ in LPS-stimulated BMDM and RAW264.7 cells. In addition, LPS markedly increased mRNA expression and release levels of pro-inflammatory cytokines and mediators such as interleukin (IL)-1β, IL-6, tumor necrosis factor-α, cyclooxygenase-2, nitric oxide and prostaglandin E2, whereas these increases were substantially down-regulated by rhKAI1. Furthermore, LPS strongly increased expression of NF-κB p65 in the nuclei and phosphorylation of ERK, JNK, and p38 MAPK. However, nuclear translocation of NF-κB p65 and phosphorylation of JNK were greatly reversed in the presence of rhKAI1. Especially, rhKAI1 markedly suppressed expression of toll-like receptor (TLR4) and prevented binding of LPS with TLR4 through molecular docking predict analysis. Importantly, Glu 214 of rhKAI1 residue strongly interacted with Lys 360 of TLR4 residue, with a binding distance of 2.9 Å. Taken together, these findings suggest that rhKAI1 has an anti-inflammatory effect on LPS-polarized macrophages by interacting with TLR4 and down-regulating the JNK/NF-κB signaling pathway. [BMB Reports 2023; 56(6): 359-364].

Indexed as

LipopolysaccharidesNF-kappa BAnimalsAnti-Inflammatory AgentsCytokinesHumansKangai-1 ProteinMacrophagesMAP Kinase Signaling SystemMiceMolecular Docking SimulationRAW 264.7 CellsToll-Like Receptor 4Anti-Inflammatory AgentsCD82 protein, humanCytokinesKangai-1 ProteinLipopolysaccharidesNF-kappa BTLR4 protein, humanToll-Like Receptor 4

Identifiers

PMID36945827
PMCPMC10315567
OpenAlexW4327905462

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.